AURINIA PHARMACEUTICALS INC (AUPH) Fundamental Analysis & Valuation

NASDAQ:AUPH • CA05156V1022

Current stock price

15.96 USD
+0.07 (+0.44%)
At close:
15.96 USD
0 (0%)
After Hours:

This AUPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. AUPH Profitability Analysis

1.1 Basic Checks

  • In the past year AUPH was profitable.
  • AUPH had a positive operating cash flow in the past year.
  • In multiple years AUPH reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: AUPH reported negative operating cash flow in multiple years.
AUPH Yearly Net Income VS EBIT VS OCF VS FCFAUPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • With an excellent Return On Assets value of 38.21%, AUPH belongs to the best of the industry, outperforming 98.26% of the companies in the same industry.
  • AUPH has a better Return On Equity (49.40%) than 98.45% of its industry peers.
  • The Return On Invested Capital of AUPH (12.51%) is better than 95.16% of its industry peers.
Industry RankSector Rank
ROA 38.21%
ROE 49.4%
ROIC 12.51%
ROA(3y)8.34%
ROA(5y)-6.25%
ROE(3y)10.1%
ROE(5y)-6.84%
ROIC(3y)N/A
ROIC(5y)N/A
AUPH Yearly ROA, ROE, ROICAUPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • AUPH has a Profit Margin of 101.47%. This is amongst the best in the industry. AUPH outperforms 98.45% of its industry peers.
  • AUPH's Operating Margin of 37.65% is amongst the best of the industry. AUPH outperforms 96.91% of its industry peers.
  • AUPH has a better Gross Margin (88.46%) than 89.94% of its industry peers.
  • AUPH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 37.65%
PM (TTM) 101.47%
GM 88.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5YN/A
AUPH Yearly Profit, Operating, Gross MarginsAUPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AUPH Health Analysis

2.1 Basic Checks

  • AUPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for AUPH has been reduced compared to 1 year ago.
  • AUPH has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AUPH has been reduced compared to a year ago.
AUPH Yearly Shares OutstandingAUPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
AUPH Yearly Total Debt VS Total AssetsAUPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • AUPH has an Altman-Z score of 7.72. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of AUPH (7.72) is better than 78.92% of its industry peers.
  • AUPH has a debt to FCF ratio of 0.51. This is a very positive value and a sign of high solvency as it would only need 0.51 years to pay back of all of its debts.
  • The Debt to FCF ratio of AUPH (0.51) is better than 95.55% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that AUPH is not too dependend on debt financing.
  • The Debt to Equity ratio of AUPH (0.09) is worse than 62.48% of its industry peers.
  • Although AUPH's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.51
Altman-Z 7.72
ROIC/WACC1.53
WACC8.15%
AUPH Yearly LT Debt VS Equity VS FCFAUPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 5.25 indicates that AUPH has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.25, AUPH is in line with its industry, outperforming 57.45% of the companies in the same industry.
  • AUPH has a Quick Ratio of 4.76. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 4.76, AUPH perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.25
Quick Ratio 4.76
AUPH Yearly Current Assets VS Current LiabilitesAUPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AUPH Growth Analysis

3.1 Past

  • AUPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 800.00%, which is quite impressive.
  • AUPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.38%.
  • The Revenue has been growing by 41.39% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2500%
Revenue 1Y (TTM)20.38%
Revenue growth 3Y28.31%
Revenue growth 5Y41.39%
Sales Q2Q%28.81%

3.2 Future

  • Based on estimates for the next years, AUPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.23% on average per year.
  • AUPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.00% yearly.
EPS Next Y1.75%
EPS Next 2Y10.95%
EPS Next 3Y17.04%
EPS Next 5Y9.23%
Revenue Next Year16.21%
Revenue Next 2Y15.98%
Revenue Next 3Y16.1%
Revenue Next 5Y13%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AUPH Yearly Revenue VS EstimatesAUPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AUPH Yearly EPS VS EstimatesAUPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. AUPH Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 19.70, AUPH is valued on the expensive side.
  • Based on the Price/Earnings ratio, AUPH is valued cheaper than 93.62% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of AUPH to the average of the S&P500 Index (26.91), we can say AUPH is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 19.37 indicates a rather expensive valuation of AUPH.
  • AUPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 94.39% of the companies in the same industry.
  • AUPH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 19.7
Fwd PE 19.37
AUPH Price Earnings VS Forward Price EarningsAUPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 95.74% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, AUPH is valued cheaper than 96.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.67
EV/EBITDA 11.63
AUPH Per share dataAUPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AUPH does not grow enough to justify the current Price/Earnings ratio.
  • AUPH has a very decent profitability rating, which may justify a higher PE ratio.
  • AUPH's earnings are expected to grow with 17.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)11.27
PEG (5Y)N/A
EPS Next 2Y10.95%
EPS Next 3Y17.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AUPH Dividend Analysis

5.1 Amount

  • No dividends for AUPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AUPH Fundamentals: All Metrics, Ratios and Statistics

AURINIA PHARMACEUTICALS INC

NASDAQ:AUPH (4/9/2026, 8:12:48 PM)

After market: 15.96 0 (0%)

15.96

+0.07 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)04-30
Inst Owners55.01%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change0.9%
Market Cap2.12B
Revenue(TTM)283.06M
Net Income(TTM)287.20M
Analysts78.46
Price Target17.34 (8.65%)
Short Float %8.21%
Short Ratio9.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.29%
Min EPS beat(2)17.65%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)30.6%
Min EPS beat(4)6.95%
Max EPS beat(4)56.86%
EPS beat(8)8
Avg EPS beat(8)116.68%
EPS beat(12)11
Avg EPS beat(12)87.01%
EPS beat(16)14
Avg EPS beat(16)70.98%
Revenue beat(2)2
Avg Revenue beat(2)3.92%
Min Revenue beat(2)1.01%
Max Revenue beat(2)6.84%
Revenue beat(4)3
Avg Revenue beat(4)3.78%
Min Revenue beat(4)-0.48%
Max Revenue beat(4)7.75%
Revenue beat(8)6
Avg Revenue beat(8)4.25%
Revenue beat(12)9
Avg Revenue beat(12)8.35%
Revenue beat(16)13
Avg Revenue beat(16)10.05%
PT rev (1m)1.71%
PT rev (3m)1.71%
EPS NQ rev (1m)-1.98%
EPS NQ rev (3m)0.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.58%
Revenue NQ rev (1m)1.86%
Revenue NQ rev (3m)4.79%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 19.7
Fwd PE 19.37
P/S 7.5
P/FCF 15.67
P/OCF 15.64
P/B 3.65
P/tB 3.67
EV/EBITDA 11.63
EPS(TTM)0.81
EY5.08%
EPS(NY)0.82
Fwd EY5.16%
FCF(TTM)1.02
FCFY6.38%
OCF(TTM)1.02
OCFY6.39%
SpS2.13
BVpS4.37
TBVpS4.34
PEG (NY)11.27
PEG (5Y)N/A
Graham Number8.93
Profitability
Industry RankSector Rank
ROA 38.21%
ROE 49.4%
ROCE 16.2%
ROIC 12.51%
ROICexc 31.66%
ROICexgc 32.13%
OM 37.65%
PM (TTM) 101.47%
GM 88.46%
FCFM 47.84%
ROA(3y)8.34%
ROA(5y)-6.25%
ROE(3y)10.1%
ROE(5y)-6.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5YN/A
F-Score7
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.51
Debt/EBITDA 0.42
Cap/Depr 1.3%
Cap/Sales 0.09%
Interest Coverage 250
Cash Conversion 107.66%
Profit Quality 47.15%
Current Ratio 5.25
Quick Ratio 4.76
Altman-Z 7.72
F-Score7
WACC8.15%
ROIC/WACC1.53
Cap/Depr(3y)2.97%
Cap/Depr(5y)14.79%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2500%
EPS Next Y1.75%
EPS Next 2Y10.95%
EPS Next 3Y17.04%
EPS Next 5Y9.23%
Revenue 1Y (TTM)20.38%
Revenue growth 3Y28.31%
Revenue growth 5Y41.39%
Sales Q2Q%28.81%
Revenue Next Year16.21%
Revenue Next 2Y15.98%
Revenue Next 3Y16.1%
Revenue Next 5Y13%
EBIT growth 1Y478.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y206.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y205.62%
OCF growth 3YN/A
OCF growth 5YN/A

AURINIA PHARMACEUTICALS INC / AUPH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 6 / 10 to AUPH.


What is the valuation status of AURINIA PHARMACEUTICALS INC (AUPH) stock?

ChartMill assigns a valuation rating of 6 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Fairly Valued.


How profitable is AURINIA PHARMACEUTICALS INC (AUPH) stock?

AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 6 / 10.


What is the valuation of AURINIA PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 19.7 and the Price/Book (PB) ratio is 3.65.